Unique ID issued by UMIN | UMIN000024753 |
---|---|
Receipt number | R000028256 |
Scientific Title | A clinical trial of efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2 |
Date of disclosure of the study information | 2016/12/01 |
Last modified on | 2020/11/11 13:20:11 |
A clinical trial of efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2
A clinical trial of efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2
A clinical trial of efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2
A clinical trial of efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2
Japan |
progressive familial intrahepatic cholestasis type 2
Pediatrics |
Others
NO
To evaluate the efficacy and safety of sodium phenylbutyrate in progressive familial intrahepatic cholestasis type 2
Safety,Efficacy
Exploratory
Explanatory
Phase II
To evaluate liver histopathology before and after 24-weeks treatment with sodium phenylbutylate
1)Liver histopathological score
2)Reliability of histopathological scoring system
3)Biomarkers such as AST, ALT, g-GTP, T.Bil, D.Bil
4)Itching
5)Biomarkers such as plasma amino acid fraction (isoleucine, glutamine, glutamic acid, argineine), and anmonia
6)Survival rate
7)Liver transplantation avoidance rate
8)Pharmacokinetics
9)Adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
To subscribe 450 or 600mg/kg/day sodium phenylbutylate (buphenyl) for 24 weeks
Not applicable |
Not applicable |
Male and Female
1)Patients who are diagnosed with PFIC type 2
2)Hospitalised- or out-patients
3)Those who can intake medicine per oral and continue the treatment
4)Those who can receive the observation necessary in this study
5) Those who have given written informed consent on the use of their data for the study (patients or legally acceptable representative)
1)Those who participated in another study within 3 months
2)Those who have hypersensitivity with phenylbutylate and/or its metabolite
3)Those who received liver transplantation
4)Those who received biliary diversion
5)Those who are pregnant or hoping pregnancy
6)Those who cannot accept to practice contraception
7)Those with congestive heart failure
8)Those with renal dysfunction
9)Those with nonsense or frameshift mutation, or exon deletion in both ABCB11 alleles
10) Those with liver cirrhosis
6
1st name | Hiroki |
Middle name | |
Last name | Kondou |
Kindai University Nara Hospital
Department of Pediatrics
630-0293
1248-1 Otoda-cho, Ikoma, Nara, Japan
0743-77-0880
kondou-hiroki@med.kindai.ac.jp
1st name | Hiroki |
Middle name | |
Last name | Kondou |
Kindai University Nara Hospital
Department of Pediatrics
630-0293
1248-1 Otoda-cho, Ikoma, Nara, Japan
0743-77-0880
kondou-hiroki@med.kindai.ac.jp
Japan Agency for Medical Research and Development
Japan Agency for Medical Research and Development
Government offices of other countries
Osaka University
2-15 Yamadaoka, Suita-shi, Osaka
06-6210-8290
shiken@hp-crc.med.osaka-u.ac.jp
NO
大阪大学医学部附属病院(大阪府)、順天堂大学附属順天堂医院(東京都)、久留米大学病院(福岡県)、鳥取大学医学部附属病院(鳥取県)、宮城県立こども病院(宮城県)
2016 | Year | 12 | Month | 01 | Day |
Unpublished
6
Delay expected |
Because it took a long time to meet the target number of cases.
No longer recruiting
2016 | Year | 09 | Month | 27 | Day |
2016 | Year | 09 | Month | 27 | Day |
2016 | Year | 11 | Month | 18 | Day |
2021 | Year | 03 | Month | 31 | Day |
2016 | Year | 11 | Month | 08 | Day |
2020 | Year | 11 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028256